Skip to main content
Premium Trial:

Request an Annual Quote

Centogene, Evotec Forge Drug-Discovery Alliance

NEW YORK (GenomeWeb) — German multiomics tools firm Centogene announced today that it has partnered with Evotec to discover and develop drugs for certain rare genetic diseases.

Under the terms of the strategic alliance, the companies will combine Evotec's induced pluripotent stem cell-based drug screening platform with Centogene's patient access and biomarker expertise to develop a high-throughput platform for evaluating novel small molecule treatments for rare hereditary metabolic diseases.

Additional terms were not disclosed.

"The identification and development of innovative small molecules to treat rare hereditary conditions is particularly challenging because of the absence of adequate cellular models and the general lack of specific biomarkers to monitor the different diseases," Centogene CEO Arndt Rolfs said in a statement. "With this innovative collaboration between Evotec and Centogene, we can accelerate the development of new drugs."

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.